Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Other Accumulated Expenses (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Other Accumulated Expenses for 4 consecutive years, with $1.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 43.88% to $1.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.7 million, a 43.88% increase, with the full-year FY2024 number at $579000.0, down 46.34% from a year prior.
  • Other Accumulated Expenses was $1.7 million for Q3 2025 at Orchestra BioMed Holdings, up from $1.1 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.9 million in Q4 2022 to a low of $579000.0 in Q4 2024.
  • A 4-year average of $1.2 million and a median of $1.1 million in 2024 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: plummeted 46.34% in 2024, then skyrocketed 43.88% in 2025.
  • Orchestra BioMed Holdings' Other Accumulated Expenses stood at $1.9 million in 2022, then crashed by 43.0% to $1.1 million in 2023, then tumbled by 46.34% to $579000.0 in 2024, then surged by 192.23% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Other Accumulated Expenses are $1.7 million (Q3 2025), $1.1 million (Q1 2025), and $579000.0 (Q4 2024).